Study of Depression-Ketamine-Brain Function

Pilot Study Probing the Antidepressant Effects of 0.5 mg/kg Intravenous Ketamine in Drug-resistant Depressed Patients (Unipolar Depression): Efficacy, Safety, Brain Function

Targeting the glutamatergic system to treat depression is a new and promising strategy based on studies at the molecular, synaptic, and neuronal level but also on results of studies conducted in animal models and first clinical studies involving depressed patients.Ketamine has been proposed as a novel approach to induce rapid antidepressant response. In this pilot project the investigators aim to introduce this novel and promising approach into clinical practice. Besides the assessment of clinical efficacy, the investigators will put a special emphasis on the assessment of ketamine-associated effects on brain function using fMRI and cognitive testing.

Study Overview

• Status: Terminated
• Conditions: Major Depression
• Intervention / Treatment: Drug: Ketamine

• Study Type: Interventional
• Enrollment (Actual): 10
• Phase: Phase 2

Contacts and Locations

Study Locations

• Switzerland
  • Geneva, Switzerland, 1207
    • Service de Psychiatrie Adulte, Programme dépression

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 65 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Men and women aged 18 to 65 years with a diagnosis of major depressive disorder without psychotic features.
• Drug-resistant depressed patients (defined as non-response to two sufficiently long (at least 6 weeks) drug trials at the maximal authorized or tolerated dose)
• Score 25 or higher on the Montgomery-Asberg Depression Rating Scale
• Stable psychotropic medication (antidepressants, antipsychotics, mood stabilizers) during the last 6 weeks prior to inclusion.
• Legally competent subjects agreeing to comply with the requirements of the study and authorizing the transmission of relevant information to competent physicians in the case of a clinically relevant previously unknown finding during an MRI examination.

Exclusion Criteria:

• Subjects with co-morbid substance abuse or dependence during the 3 months prior to inclusion, except nicotine consumption.
• Patients judged to be at serious suicide risk (score ≥ 4 at item 10 of the MADRS).
• Patients with any other DSM-IV axis one diagnosis including bipolar disorder except for anxiety disorder which are not dominating the clinical presentation.
• History of antidepressant or substance-induced hypomania or mania.
• History of psychotic symptoms.
• Patients with any contra-indication to the administration of ketamine, especially present diagnosis or antecedents of clinically relevant cardiovascular disorders (clinically significant or not adequately treated hypertension, present or previous diagnosis of cardiovascular disorder such as stroke or heart attack etc).
• Any MRI contraindication, especially metallic implants, pacemaker, etc.
• Pregnant women, breast-feeding women, women of childbearing age without effective means of contraception.
• Treatment during the last 2 weeks with thyroid hormones and sympathicomimetic drug.
• Present or past diagnosis of eclampsia or preeclampsia.
• Untreated or insufficiently treated hyperthyroidism.
• Known hypersensitivity to ketamine or to the excipient (benzethonium chloride).
• Present or past diagnosis of glaucoma, intracranial hypertension.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: ketamine 0.5 mg/kg i.v.; Single administration of ketamine 0.5 mg/kg i.v.	Drug: Ketamine; Administration of a subanaesthetic dose of Ketamine, intravenously (0.5 mg/kg)

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Difference of the MADRS score at baseline and after ketamine injection	40, 80, 110, 230 min, 1, 2, 3, 6, 7, 10 d after ketamine administration

Collaborators and Investigators

• Sponsor: Markus KOSEL
• Investigators: Principal Investigator: Markus Kosel, MD-PhD, Departement of Adult Psychiatry, University Hospital of Geneva

Study record dates

Study Major Dates

• Study Start: June 1, 2010
• Primary Completion (Actual): June 1, 2015
• Study Completion (Actual): September 1, 2015

Study Registration Dates

• First Submitted: June 2, 2010
• First Submitted That Met QC Criteria: June 2, 2010
• First Posted (Estimate): June 3, 2010

Study Record Updates

• Last Update Posted (Estimate): December 7, 2015
• Last Update Submitted That Met QC Criteria: December 4, 2015
• Last Verified: December 1, 2015

More Information

Terms related to this study

• Keywords: depression, ketamine, fMRI
• Additional Relevant MeSH Terms: Behavioral Symptoms; Mental Disorders; Mood Disorders; Depression; Depressive Disorder; Physiological Effects of Drugs; Neurotransmitter Agents; Molecular Mechanisms of Pharmacological Action; Central Nervous System Depressants; Peripheral Nervous System Agents; Analgesics; Sensory System Agents; Anesthetics, Dissociative; Anesthetics, Intravenous; Anesthetics, General; Anesthetics; Excitatory Amino Acid Antagonists; Excitatory Amino Acid Agents; Ketamine
• Other Study ID Numbers: CE09-144/Psy 09-22